Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

R&D Systems™ TM2 TEAD inhibitor
GREENER_CHOICESDP

Catalog No. 791750 Shop All Novus Products
Change view
Click to view available options
Quantity:
10 mg
50 mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
79-175-0 50 mg
79-171-0 10 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
This item is not returnable. View return policy
Catalog No. 79-175-0 Supplier R&D Systems™ Supplier No. 7917/50

Customers require a valid business account associated to their profile to access pricing and ordering options.

missing translation for 'validMainframeMsg'

This item is not returnable. View return policy

A Tocris product, part of R&D Systems. Potent and reversible inhibitor of TEAD mediated Hippo/Yap signalling

TM2 TEAD inhibitor is a potent and reversible TEA domain transcription factor inhibitor (IC50 = 38 nM and 156 nM for TEAD4 auto-palmitoylation and TEAD2 palmitoylation, respectively). It inhibits TEAD-YAP association and transcriptional activity. TM2 TEAD inhibitor exhibits strong antiproliferation effects as a single agent or in combination with a MEK inhibitor in YAP-dependent cancer cells. Also inhibits YAP-dependent liver organoid growth ex vivo.

Specifications

Chemical Name or Material 4-[3-(2-Cyclohexylethoxy)benzoyl]-N-phenyl-1-piperazinecarboxamide
CAS 1008768-41-9
Quantity 50 mg
Product Line Tocris
Target YAP1
Molecular Formula C26H33N3O3
Purity 0.98
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.